logo
  

Adagio Therapeutics Expands Patient Population In ADG20 Trial For COVID-19

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced Friday the expansion of patient population in global EVADE phase 2/3 clinical trial of ADG20 for the prevention of COVID-19.

The EVADE global trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. It evaluates the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

The independent data monitoring committee or IDMC for the trial has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women. The IDMC also recommended to decrease the protocol-specified, post injection monitoring time.

The IDMC's assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio said it plans to implement the IDMC recommendations for the Phase 3 portion of the trial.

Lynn Connolly, chief medical officer of Adagio, said, "Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 6 percent in the morning trading in Germany after the package delivery and logistic major reported Friday higher profit and revenues in its second quarter with strong demand. Going ahead, the company confirmed its 2022 EBIT guidance of 8.0 billion euros, plus or minus 5 percent, even in consideration of a possible global economic downturn. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday net income for the first quarter halved from last year, hurt by a 1 decline in revenues and a decrease in the market prices of its equity investments in publicly-traded companies. Shares of Deutsche Lufthansa AG were gaining around 6 percent in the morning trading after the German flag carrier reported Thursday a profit in its second quarter, compared to last year's loss, benefited by surge in demand. The company also specified its outlook for the year, and now expects adjusted EBIT to be above 500 million euros for the full year of 2022, in line with current market.
RELATED NEWS
Follow RTT